Cantor Fitzgerald started coverage on shares of Capricor Therapeutics (NASDAQ:CAPR – Free Report) in a report published on Friday morning, MarketBeat reports. The firm issued an overweight rating and a $8.00 price objective on the biotechnology company’s stock. A number of other equities research analysts have also recently issued reports on CAPR. StockNews.com cut Capricor […]
StockNews.com lowered shares of Capricor Therapeutics (NASDAQ:CAPR – Free Report) from a hold rating to a sell rating in a report issued on Wednesday morning. Separately, HC Wainwright raised their price target on Capricor Therapeutics from $18.00 to $40.00 and gave the stock a buy rating in a research report on Wednesday, October 4th. Get […]
Capricor Therapeutics Inc (NASDAQ:CAPR – Get Free Report) was the target of a large increase in short interest in November. As of November 15th, there was short interest totalling 1,360,000 shares, an increase of 10.6% from the October 31st total of 1,230,000 shares. Based on an average trading volume of 253,500 shares, the days-to-cover ratio […]
StockNews.com upgraded shares of Capricor Therapeutics (NASDAQ:CAPR – Free Report) from a sell rating to a hold rating in a research report released on Friday morning. Separately, HC Wainwright lifted their price objective on Capricor Therapeutics from $18.00 to $40.00 and gave the stock a buy rating in a research report on Wednesday, October 4th. […]
Capricor Therapeutics Inc (NASDAQ:CAPR – Get Free Report) was the target of a significant growth in short interest in the month of September. As of September 30th, there was short interest totalling 669,100 shares, a growth of 22.2% from the September 15th total of 547,600 shares. Based on an average daily trading volume, of 211,700 […]